Arix Bioscience Résultats passés
Passé contrôle des critères 2/6
Arix Bioscience's earnings have been declining at an average annual rate of -16.4%, while the Capital Markets industry saw earnings growing at 16.6% annually. Revenues have been declining at an average rate of 21.3% per year. Arix Bioscience's return on equity is 6.3%, and it has net margins of 105.6%.
Informations clés
-16.4%
Taux de croissance des bénéfices
-18.5%
Taux de croissance du BPA
Capital Markets Croissance de l'industrie | 16.3% |
Taux de croissance des recettes | -21.3% |
Rendement des fonds propres | 6.3% |
Marge nette | 105.6% |
Dernière mise à jour des bénéfices | 30 Jun 2023 |
Mises à jour récentes des performances passées
Ventilation des recettes et des dépenses
Comment Arix Bioscience gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
30 Jun 23 | 14 | 15 | 6 | 0 |
31 Mar 23 | -8 | -6 | 6 | 0 |
31 Dec 22 | -31 | -28 | 5 | 0 |
30 Sep 22 | -40 | -40 | 5 | 0 |
30 Jun 22 | -50 | -53 | 5 | 0 |
31 Mar 22 | -52 | -57 | 5 | 0 |
31 Dec 21 | -54 | -61 | 5 | 0 |
30 Sep 21 | 4 | -11 | 6 | 0 |
30 Jun 21 | 61 | 39 | 7 | 0 |
31 Mar 21 | 98 | 83 | 7 | 0 |
31 Dec 20 | 136 | 126 | 8 | 0 |
30 Sep 20 | 78 | 72 | 8 | 0 |
30 Jun 20 | 20 | 18 | 9 | 0 |
31 Mar 20 | -21 | -26 | 11 | 0 |
31 Dec 19 | -62 | -70 | 12 | 0 |
30 Sep 19 | -42 | -49 | 14 | 0 |
30 Jun 19 | -22 | -28 | 15 | 0 |
31 Mar 19 | 15 | 5 | 15 | 0 |
31 Dec 18 | 53 | 37 | 15 | 0 |
30 Sep 18 | 47 | 31 | 15 | 0 |
30 Jun 18 | 42 | 25 | 14 | 0 |
31 Mar 18 | 25 | 9 | 14 | 0 |
31 Dec 17 | 7 | -7 | 14 | 0 |
31 Dec 16 | 1 | -7 | 11 | 0 |
31 Mar 16 | 0 | -7 | 6 | 0 |
Des revenus de qualité: ARIX has high quality earnings.
Augmentation de la marge bénéficiaire: ARIX became profitable in the past.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: ARIX's earnings have declined by 16.4% per year over the past 5 years.
Accélération de la croissance: ARIX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Bénéfices par rapport au secteur d'activité: ARIX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Capital Markets industry (-3%).
Rendement des fonds propres
ROE élevé: ARIX's Return on Equity (6.3%) is considered low.